• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BARDA awards Novan $7.8 million contract

BARDA awards Novan $7.8 million contract

August 27, 2013
CenterWatch Staff

The U.S. Department of Health and Human Services has entered into a contract with Novan, a clinical-stage drug development company focused on topical delivery of nitric oxide, to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. 

The Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response, awarded this contract. It is believed a mass casualty event caused by natural or intentional threats to public health could result in tens of thousands of burn patients, which would overwhelm the burn care infrastructure available in hospitals across the U.S. 

BARDA will provide $7.8 million in funding over two years. The contract will support the pharmaceutical development of the Nitric Oxide Advanced Healing (NOAH) technology including formulation work, nonclinical toxicology and proof of concept studies in models of deep partial thickness and full thickness thermal injuries. This project is designed to enable the future clinical investigation of the medical countermeasure.

"The link between nitric oxide and the body's ability to heal is well established,” said Nathan Stasko, president of Novan.  “The challenge is to create stable nitric oxide drugs that 'perform on command' and deliver a controlled, sustained dose that will supplement the body's ability to regenerate tissue. Our platform technology has allowed us to pursue the development of drugs intended to harness the healing power of nitric oxide with results extending beyond bioterrorism. We believe the NOAH technology creates a gateway into regenerative medicine and could lead to therapies that can help heal both acute and chronic wounds."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing